Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chawki Lahoud

Internal Medicine Raleigh, NC Medical Doctor

NPI 1730133604 CMS profile 1067485

4505 Fair Meadows Ln Ste 101, Raleigh, NC 27607

Open in the dashboard

General payments

$12,021

531 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chawki Lahoud of Raleigh, NC is reported in the CMS Open Payments database as having received $12,021 across 531 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,924 68
2024 General $1,381 47
2023 General $1,255 47
2022 General $1,575 69
2021 General $2,544 123
2020 General $1,209 70
2019 General $2,133 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chawki Lahoud
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Chawki Lahoud were reported at $1,924. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Chawki Lahoud Internal Medicine median Middle half National median
2019 $2,133 $159 $48–$570 $163
2020 $1,209 $119 $33–$402 $114
2021 $2,544 $135 $37–$521 $132
2022 $1,575 $141 $42–$496 $149
2023 $1,255 $149 $45–$519 $160
2024 $1,381 $154 $47–$537 $164
2025 $1,924 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,215 109 payments
  2. Novo Nordisk Inc $2,252 113 payments
  3. Lilly USA, LLC $989 46 payments
  4. GlaxoSmithKline, LLC. $955 49 payments
  5. Amgen Inc. $889 36 payments
  6. AbbVie, Inc. $787 39 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $472 17 payments
  8. Allergan Inc. $310 28 payments
  9. Medtronic, Inc. $197 2 payments
  10. ITI, Inc. $195 11 payments
  11. Other $1,760 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,989 528 payments
  2. Education $32 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,560 88 payments
  2. FARXIGA $1,519 61 payments
  3. RYBELSUS $1,416 66 payments
  4. BREZTRI $557 11 payments
  5. TRELEGY ELLIPTA $545 23 payments
  6. AIRSUPRA $520 15 payments
  7. MOUNJARO $507 13 payments
  8. Kerendia $472 17 payments
  9. FASENRA $444 10 payments
  10. Otezla $400 27 payments
  11. Other $6,244 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

10,585

Median for Emergency Medicine: 88

Drug cost

$2,298,548

Median for Emergency Medicine: $590

Branded share of claims

30.6%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 460 $508,948
Ozempic Semaglutide Brand 181 $258,039
Trulicity Dulaglutide Brand 141 $236,421
Farxiga Dapagliflozin Propanediol Brand 205 $198,984
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 163 $142,047
Jardiance Empagliflozin Brand 98 $132,263
Rybelsus Semaglutide Brand 74 $115,673
Restasis Cyclosporine Brand 82 $92,192
Vascepa Icosapent Ethyl Brand 108 $78,382
Mounjaro Tirzepatide Brand 57 $63,224

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$26,881

Of which drugs: $884

Medicare patients

84

Average age 69

Services billed

766

45 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
Arthritis 35%
Ischemic heart disease 21%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $354
$354 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $176
$176 — —
Repatha
  • Amgen Inc. $136
$136 — —
MOUNJARO
  • Lilly USA, LLC $131
$131 57 —
RYBELSUS
  • Novo Nordisk Inc $116
$116 74 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

531 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record